Robert S. Rosenson

May 29, 2024 | healio.com | Erik Swain |Richard Smith |Christie M. Ballantyne |Robert S. Rosenson

You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Two small interfering RNA therapies lowered triglyceride levels in patients with mixed hyperlipidemia at 24 weeks. They also lowered non-HDL and apolipoprotein B.

Sep 13, 2023 | healio.com | Scott Buzby |Richard Smith |Robert S. Rosenson

Source/Disclosures Disclosures: Rosenson reports receiving grants and/or personal fees from Amgen, Arrowhead, Avilar Therapeutics, CRISPR Therapeutics, Eli Lilly, Kowa, Lipigon, Merck, Novartis, Precision BioSciences, Regeneron, UpToDate, UltraGenyx and Verve Therapeutics and holding equity in MediMergent. You've successfully added Cardiology: CHD/Prevention to your alerts. You will receive an email when new content is published.